An Open-label, Randomized Phase III Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Conditions

Leukemia, other

What is the purpose of this trial?

This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.


Participation Guidelines

Age:
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Pfizer Inc., U.S. Pharmaceuticals Group
Dates:
08/20/2013
Last Updated:
Study HIC#:
1301011417